Evidence map›Paper›PMID 37444626›Full record

ArticleCancers2023

Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone-A Retrospective Study.

Hao Xiang Chen, Li-Hsien Tsai, Chao-Hsiang Chang, Hsi-Chin Wu, Ching-Chan Lin, Che-Hung Lin, Chin-Chung Yeh, Chi-Rei Yang, Chi-Shun Lien, Yi-Huei Chang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Hao Xiang ChenDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0002-0153-1570
Li-Hsien TsaiDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0002-2475-8284
Chao-Hsiang ChangDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Hsi-Chin WuDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Ching-Chan LinDepartment of Internal Medicine, Division of Hematology and Oncology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Che-Hung LinDepartment of Internal Medicine, Division of Hematology and Oncology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Chin-Chung YehDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Chi-Rei YangDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Chi-Shun LienDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Yi-Huei ChangDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Ji-An LiangSchool of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan.
Guan-Heng ChenDepartment of Urology, China Medical University Hsinchu Hospital, Hsinchu 30272, Taiwan.
Po-Jen HsiaoDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0002-0989-7876
Po-Fan HsiehDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Chi-Ping HuangDepartment of Urology, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
China Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is a progressive stage of prostate cancer that often spreads to the bone. Radium-223, a bone-targeting radiopharmaceutical, has been shown to improve the overall survival in mCRPC in patients without visceral metastasis. However, the impact of prior systemic therapy on the treatment outcome of mCRPC patients receiving radium-223 remains unclear. This study aimed to investigate the optimal choice of systemic therapy before radium-223 in mCRPC patients. The study included 41 mCRPC patients who received radium-223 therapy, with 22 receiving prior enzalutamide and 19 receiving prior abiraterone. The results showed that the median overall survival was significantly longer in the enzalutamide group than in the abiraterone group (25.1 months vs. 14.8 months,

Indexed as

abirateroneenzalutamidemetastatic castration resistant prostate cancerradium-223sequence

Identifiers

PMID37444626
PMCPMC10340515
OpenAlexW4383552306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.